Operating Margin (Quarterly)

Operating Margin: Operating margin measurement of what proportion of a company's revenue is left over after paying for variable costs of production such as wages, raw materials, etc. Calculated as: Operating Income / Total Revenues

Cytokinetics, Incorporated (CYTK) had Operating Margin of -8613.38% for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$1.94M
Net Income	$-306.18M
Cost of Goods Sold	--
Gross Profit	$1.94M
Operating Expenses	$168.69M
Operating Income	$-166.75M
Non-Operating Income/Expense	$-139.42M
Pre-Tax Income	$-306.18M
Normalized Pre-Tax Income	$-306.18M
Income after Taxes	$-306.18M
Income from Continuous Operations	$-306.18M
Consolidated Net Income/Loss	$-306.18M
Normalized Income after Taxes	$-306.18M
EBIT	$-166.75M
EBITDA	$-164.08M
Weighted-Average Shares Outstanding (Basic)	119.98M
Weighted-Average Shares Outstanding (Diluted)	119.98M
Earnings per Share (EPS) (Basic)	$-2.55
Earnings per Share (EPS) (Diluted)	$-2.55
Balance Sheet Financials
Current Assets	$977.35M
Property, Plant, and Equipment	$76.00M
Long-Term Assets	$459.21M
Total Assets	$1.44B
Current Liabilities	$142.14M
Long-Term Debt	$1.05B
Long-Term Liabilities	$1.82B
Total Liabilities	$1.96B
Common Equity	$-521.12M
Tangible Shareholders Equity	$-521.12M
Shareholders Equity	$-521.12M
Common Shares Outstanding	122.12M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-367.36M
Cash Flow from Investing Activities	$87.86M
Cash Flow from Financial Activities	$413.75M
Beginning Cash	$95.23M
End Cash	$228.58M
Increase/Decrease in Cash	$133.35M
Stock-Based Compensation	$81.78M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	6.88
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	1.99
Debt to Equity Ratio	-2.08
Gross Margin	100.00%
Operating Margin	-8613.38%
EBIT Margin	-8613.38%
EBITDA Margin	--
Pre-Tax Profit Margin	-15814.98%
Profit Margin	-15814.98%
Free Cash Flow	$-386.52M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.00
Inventory Turnover	--
Receiveable Turnover	1.07
Days Sales in Receivables	84.05
Return on Equity	58.75%
Return on Tangible Equity	58.75%
Return on Assets	-21.31%
Return on Investments	-58.08%
Book Value Per Share	$-4.27
Free Cash Flow per Share	$-3.22
Operating Cash Flow per Share	$-3.06

Data from Zacks Investment Research, Inc.